As regards the 2008 share-based payment program implemented in the fiscal year under review, the applicable quantities and monetary values of share options at the date of grant have been presented in the following table:
|
|
|
|
|
| ||
|
|
Share-based payment program 2009 |
Share-based payment program 2008 | ||||
|
|
Quantity |
Value per option1 |
Total value of compensation component with long-term incentive effect1 |
Quantity | ||
| ||||||
|
Eckard Heidloff |
60,000 |
7.65 |
459,000.00 |
60,000 | ||
|
Stefan Auerbach |
30,000 |
7.65 |
229,500.00 |
30,000 | ||
|
Dr. Jürgen Wunram |
44,000 |
7.65 |
336,600.00 |
44,000 | ||
|
Total |
134,000 |
– |
1,025,100.00 |
134,000 | ||
The share options attributable to the 2008 and 2009 share-based payment programs are not exercisable as at September 30, 2009.
In the year under review, the share options granted under the 2007 share-based payment program lapsed without any entitlement to a substitute or compensation, since the average price of Wincor Nixdorf shares in the exercise period was below the exercise price for the 2007 share-based payment program.
The total value of the share options at the date of granting was determined by means of the Black-Scholes-Merton options pricing model. Thus, the reported value of share-based compensation is merely to be seen as an amount derived from mathematical calculations. Whether the share-based compensation components associated with the current 2008 and 2009 programs result in a payment, and if so, to what extent, will depend on the future performance of the Company’s share price and the stock market price applicable during the exercise period.
The personnel expenses recognized in connection with the share-based payment programs from 2006 to 2009 can be distributed among the Board members as follows:
|
|
|
€ |
|
|
2008/2009 |
2007/2008 |
|
Eckard Heidloff |
512,150.00 |
408,638.00 |
|
Stefan Auerbach |
256,075.00 |
214,163.00 |
|
Dr, Jürgen Wunram |
375,577.00 |
285,230.00 |
|
Jürgen Wilde |
25,750.00 |
81,488.00 |
|
|
1,169,552.00 |
989,519.00 |
Please refer to 16 in the notes to the Group financial statements for further details about the range of exercise prices, the remaining term of the respective options, the average exercise price of the share options during the exercise period, as well as the conditions of option grant and exercise associated with the share-based payment programs.
